New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 11, 2012
08:08 EDTARIAARIAD announces 12-month data from PACE trial of ponatinib
ARIAD Pharmaceuticals announced twelve-month follow-up data from the pivotal PACE trial of ponatinib, its investigational BCR-ABL inhibitor, in heavily pretreated patients with advanced forms of chronic myeloid leukemia or Philadelphia chromosome-positive acute lymphoblastic leukemia. The study now shows that 57 percent of accelerated-phase CML patients in the trial, including 50 percent of patients with the T315I mutation, achieved a major hematologic response, the primary end-point for patients with advanced disease in the trial.
News For ARIA From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 10, 2014
12:11 EDTARIAOptions with increasing implied volatility
Subscribe for More Information
09:00 EDTARIAOn The Fly: Pre-market Movers
Subscribe for More Information
07:46 EDTARIAARIAD announces PRAC of EMA recommends Iclusig for continued EU use
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use